| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PLK1 |
| Uniprot No | P53350 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-603aa |
| 氨基酸序列 | MSAAVTAGKL ARAPADPGKA GVPGVAAPGA PAAAPPAKEI PEVLVDPRSR RRYVRGRFLG KGGFAKCFEI SDADTKEVFA GKIVPKSLLL KPHQREKMSM EISIHRSLAH QHVVGFHGFF EDNDFVFVVL ELCRRRSLLE LHKRRKALTE PEARYYLRQI VLGCQYLHRN RVIHRDLKLG NLFLNEDLEV KIGDFGLATK VEYDGERKKT LCGTPNYIAP EVLSKKGHSF EVDVWSIGCI MYTLLVGKPP FETSCLKETY LRIKKNEYSI PKHINPVAAS LIQKMLQTDP TARPTINELL NDEFFTSGYI PARLPITCLT IPPRFSIAPS SLDPSNRKPL TVLNKGLENP LPERPREKEE PVVRETGEVV DCHLSDMLQQ LHSVNASKPS ERGLVRQEEA EDPACIPIFW VSKWVDYSDK YGLGYQLCDN SVGVLFNDST RLILYNDGDS LQYIERDGTE SYLTVSSHPN SLMKKITLLK YFRNYMSEHL LKAGANITPR EGDELARLPY LRTWFRTRSA IILHLSNGSV QINFFQDHTK LILCPLMAAV TYIDEKRDFR TYRLSLLEEY GCCKELASRL RYARTMVDKL LSSRSASNRL KAS |
| 预测分子量 | 70 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PLK1重组蛋白研究的代表性文献摘要(提示：文献信息为模拟示例，建议通过PubMed等数据库核实具体文献)：
1. **"Structural insights into human PLK1 kinase activation through recombinant expression and crystallography"**
- **作者**: Johnson, R. et al.
- **摘要**: 通过大肠杆菌重组表达系统获得人源PLK1激酶结构域，解析其晶体结构，揭示激酶活性调控的磷酸化位点及构象变化机制。
2. **"Functional characterization of recombinant PLK1 in mitotic progression using baculovirus-insect cell system"**
- **作者**: Watanabe, N. & Kitagawa, D.
- **摘要**: 利用杆状病毒-昆虫细胞系统重组表达全长PLK1蛋白，证实其磷酸化CDC25C等底物的能力，并验证其在细胞周期G2/M期转换中的关键作用。
3. **"Development of a high-throughput screening platform using recombinant PLK1 for anticancer drug discovery"**
- **作者**: Liu, X. et al.
- **摘要**: 通过真核表达系统纯化活性PLK1重组蛋白，建立基于激酶活性的体外筛选模型，成功鉴定出新型PLK1小分子抑制剂，具有潜在抗癌应用价值。
4. **"Recombinant PLK1 purification and enzymatic activity analysis in vitro"**
- **作者**: Strebhardt, K. & Ullrich, A.
- **摘要**: 优化PLK1重组蛋白的纯化流程，通过体外激酶实验系统评估其底物特异性及ATP结合特性，为靶向PLK1的分子机制研究提供工具。
**注意**：以上文献标题及内容为基于PLK1研究的典型方向模拟生成，实际文献需通过数据库(如PubMed、Web of Science)以“PLK1 recombinant protein”等关键词检索获取。
Polo-like kinase 1 (PLK1) is a serine/threonine protein kinase that plays a pivotal role in regulating cell cycle progression, particularly during mitosis. It belongs to the evolutionarily conserved Polo-like kinase family, characterized by a C-terminal Polo-box domain (PBD) that mediates substrate interactions and subcellular localization. PLK1 is essential for multiple mitotic events, including centrosome maturation, spindle assembly, chromosome segregation, and cytokinesis. Its activity peaks during the G2/M phase, where it phosphorylates downstream targets to ensure accurate division and genomic stability. Dysregulation of PLK1 has been strongly linked to cancer, as its overexpression is observed in various tumors and correlates with poor prognosis, making it a compelling therapeutic target.
Recombinant PLK1 proteins are engineered versions of the kinase produced in heterologous expression systems (e.g., insect or mammalian cells) to enable functional studies. These proteins retain catalytic activity and structural features, including the N-terminal kinase domain and the regulatory PBD. Researchers use recombinant PLK1 to investigate its enzymatic mechanisms, screen for small-molecule inhibitors, and study interactions with regulatory proteins or substrates. In drug discovery, recombinant PLK1 serves as a tool to validate inhibitors in biochemical assays before cellular or preclinical testing. Several PLK1-targeted inhibitors (e.g., volasertib) have entered clinical trials, highlighting its translational relevance. Additionally, recombinant PLK1 aids in deciphering its non-mitotic roles, such as DNA damage response and metabolic regulation. Despite its therapeutic promise, challenges remain in achieving selective inhibition due to structural similarities with other PLK family members. Ongoing research leverages recombinant PLK1 to address these limitations and refine cancer treatment strategies.
×
